Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015578 | 0.89 | — | — | |
| SCHEMBL218758 | 0.89 | — | — | |
| Methane SCHEMBL15389723 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL31519177 | 0.87 | — | — | |
| Amifampridine SCHEMBL19423463 | 0.81 | KDM4E (0.48) | EP300KAT2BKAT8GAAKDM4E | |
| Dimethylcarbate SCHEMBL8375856 | 0.77 | KDM4C (0.50) | EP300KAT2BKAT8GAAKDM4E | |
| SCHEMBL4808842 | 0.75 | CA12 (0.44) | EP300KAT2BKAT8GAAKDM4E | |
| Sulfuric Acid SCHEMBL22717114 | 0.75 | SIRT3 (0.46) | KDM4ETDP1CA12CA2CA9 | |
| SCHEMBL394384 | 0.72 | CA12 (0.60) | CA12CA2CA9CA14CA1 | |
| SCHEMBL30014737 | 0.72 | CA12 (0.55) | CA12CA2CA9CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130330277-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | ACORDA THERAPEUTICS, INC. (US) | 2013-12-12 | — | — | US | claimed |
| US-20130072527-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | ACORDA THERAPEUTICS, INC. (US) | 2013-03-21 | — | — | US | claimed |
| EP-2343976-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | Acorda Therapeutics, Inc. (US) | 2011-07-20 | — | — | EP | claimed |
| CN-101827522-A | Continue to discharge the using method of aminopyridine compositions | ACORDA THERAPEUTICS INC | 2010-09-08 | — | — | CN | claimed |
| WO-2010030755-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | ACORDA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | WO | claimed |
| US-20100061935-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | ACORDA THERAPEUTICS, INC. (US) | 2010-03-11 | — | — | US | claimed |
| US-20130330277-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | ACORDA THERAPEUTICS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130072527-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | ACORDA THERAPEUTICS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2343976-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | Acorda Therapeutics, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| CN-101827522-A | Continue to discharge the using method of aminopyridine compositions | ACORDA THERAPEUTICS INC | 2010-09-08 | — | — | CN | disclosed |
| WO-2010030755-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | ACORDA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100061935-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | ACORDA THERAPEUTICS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072527-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | RYR2, ATP2A1, RYR1 | EP300 3799/4885KAT2B 4038/4885KAT8 4721/4885 |
| US-20130330277-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | RYR2, ATP2A1, RYR1 | EP300 3799/4885KAT2B 4038/4885KAT8 4721/4885 |
| US-20100061935-A1 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | RYR2, ATP2A1, RYR1 | EP300 3799/4885KAT2B 4038/4885KAT8 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.